Heparin Dose Calculated According to Lean Body Weight During On-pump Heart Surgery

Overview

Journal Turk Gogus Kalp Damar Cerrahisi Derg

Specialty Cardiology & Vascular Diseases

Date 2020 Feb 22

PMID 32082793

Authors

Aslihan Aykut

Ulku Sabuncu

Zeliha Asli Demir

Eda Balci

Basak Soran Turkcan

Utku Unal

Aysegul Ozgok

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study is to compare heparin dose regimen calculated based on the lean body weight with traditional heparin regimen in terms of ensuring adequate anticoagulation and complications associated with perioperative bleeding.

Methods: This prospective, single-blind, randomized study included a total of 100 adult patients (42 males, 58 females; mean age 52.7 years; range, 22 to 84 years) undergoing elective valve surgery with cardiopulmonary bypass between June 2016 and January 2017. Prior to cardiopulmonary bypass, heparin dose was adjusted as 4 mg/kg, according to the actual body weight (n=50) and lean body weight (n=50). The minimal activated clotting time target value was accepted as 480 sec for cardiopulmonary bypass initiation. Demographic and hemodynamic data, post-heparin activated clotting time, additional heparin and perioperative transfusion, postoperative drainage volumes, reoperations, and mortality were recorded.

Results: Demographic data, cross-clamp and cardiopulmonary bypass times, and intraoperative transfusion requirement were not significantly different between the groups. The initial and total doses of heparin, as well as the total dose of protamine, were significantly higher in the actual body weight group. Postoperative transfusion rates were also higher in this group. None of the patients in the lean body weight group required reoperation, while three patients in the actual body weight group underwent reoperation.

Conclusion: Our study results showed that adequate anticoagulation was achieved with the titration of heparin dose calculated according to the lean body weight during cardiopulmonary bypass and reduced total heparin and protamine doses decreased postoperative bleeding and blood product transfusion requirement.

References

Pagano D, Milojevic M, Meesters M, Benedetto U, Bolliger D, von Heymann C . 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg. 2017; 53(1):79-111. DOI: 10.1093/ejcts/ezx325. View

Charriere J, Pelissie J, Verd C, Leger P, Pouard P, De Riberolles C . Survey: retrospective survey of monitoring/safety devices and incidents of cardiopulmonary bypass for cardiac surgery in France. J Extra Corpor Technol. 2007; 39(3):142-57. PMC: 4680724. View

Canadyova J, Zmeko D, Mokracek A . Re-exploration for bleeding or tamponade after cardiac operation. Interact Cardiovasc Thorac Surg. 2012; 14(6):704-7. PMC: 3352740. DOI: 10.1093/icvts/ivs087. View

Saha K, Sangwan D, Shroff P, Deval M, Saha K, Jacob R . Off-pump coronary artery bypass grafting using continuous heparin infusion. Indian Heart J. 2016; 68(6):798-802. PMC: 5143812. DOI: 10.1016/j.ihj.2016.04.024. View

Schulman S, Bijsterveld N . Anticoagulants and their reversal. Transfus Med Rev. 2006; 21(1):37-48. DOI: 10.1016/j.tmrv.2006.08.002. View

Lobato R, Despotis G, Levy J, Shore-Lesserson L, Carlson M, Bennett-Guerrero E . Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg. 2010; 139(6):1665-6. DOI: 10.1016/j.jtcvs.2010.02.038. View

Boer C, Meesters M, Milojevic M, Benedetto U, Bolliger D, von Heymann C . 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2017; 32(1):88-120. DOI: 10.1053/j.jvca.2017.06.026. View

Levy J, Sniecinski R . Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years?. Anesth Analg. 2010; 111(4):833-5. DOI: 10.1213/ANE.0b013e3181f08a80. View

Fromes Y, Daghildjian K, Caumartin L, Fischer M, Rouquette I, Deleuze P . A comparison of low vs conventional-dose heparin for minimal cardiopulmonary bypass in coronary artery bypass grafting surgery. Anaesthesia. 2011; 66(6):488-92. DOI: 10.1111/j.1365-2044.2011.06709.x. View

10.

Jia Z, Tian G, Ren Y, Sun Z, Lu W, Hou X . Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery. J Transl Med. 2015; 13:45. PMC: 4326208. DOI: 10.1186/s12967-015-0404-5. View

11.

Hirsh J, Warkentin T, Shaughnessy S, Anand S, Halperin J, Raschke R . Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119(1 Suppl):64S-94S. DOI: 10.1378/chest.119.1_suppl.64s. View

12.

Baker M, Skoyles J, Shajar F, Skinner H, Richens D, Mitchell I . Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass?. J Extra Corpor Technol. 2005; 37(2):153-6. PMC: 4682530. View

13.

Friesen J . Lean-scaled weight: a proposed weight scalar to calculate drug doses for obese patients. Can J Anaesth. 2012; 60(2):214-5. DOI: 10.1007/s12630-012-9835-0. View

14.

Haas E, Fischer F, Levy F, Degirmenci S, Grunebaum L, Kindo M . Identifying optimal heparin management during cardiopulmonary bypass in obese patients: A prospective observational comparative study. Eur J Anaesthesiol. 2016; 33(6):408-16. DOI: 10.1097/EJA.0000000000000431. View

15.

Shuhaibar M, Hargrove M, Millat M, ODonnell A, Aherne T . How much heparin do we really need to go on pump? A rethink of current practices. Eur J Cardiothorac Surg. 2004; 26(5):947-50. DOI: 10.1016/j.ejcts.2004.07.009. View